Eris LifesciencesBOM:540596 -1.05%93 Days Payable is 162.38 as of Mar. 2026, which is 5% above its 10-year median of 154.22. GuruFocus rates BOM:540596 with a GF Score™ of 93/100 and a GF Value™ of ₹1,647.71 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 919 Drug Manufacturers companies, Eris Lifesciences ranks better than 78.45% on this metric.
The historical rank and industry rank for Eris Lifesciences's Days Payable or its related term are showing as below:
BOM:540596'
s Days Payable Range Over the Past 10 Years
Min: 123.96 Med: 154.22 Max: 243.22
Current: 162.21
During the past 13 years, Eris Lifesciences's highest Days Payable was 243.22. The lowest was 123.96. And the median was 154.22.
BOM:540596's Days Payable is ranked better than 78.45% of 919
companies
in the Drug Manufacturers industry
Industry Median: 90.69
vs BOM:540596: 162.21
Eris Lifesciences's Days Payable
declined
from Mar. 2025 (178.13) to Mar. 2026 (162.38).
It may suggest that Eris Lifesciencesaccelerated paying its suppliers.
Eris Lifesciences Days Payable Related Terms
Eris Lifesciences Days Payable Historical Data
* Premium members only.
The historical data trend for Eris Lifesciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Eris Lifesciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eris Lifesciences Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eris Lifesciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Eris Lifesciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Eris Lifesciences's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eris Lifesciences (BOM:540596) has a Days Payable of 162.38 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Eris Lifesciences and its competitors. This is near median its historical median of 154.22. Over the past decade, Eris Lifesciences' Days Payable has ranged from 123.96 to 243.22. According to the industry distribution chart, Eris Lifesciences ranks #198 out of 919 companies in the Drug Manufacturers industry, placing it in the top 21.5%.
Is Eris Lifesciences' Days Payable too high?
Eris Lifesciences' current Days Payable of 162.38 is near median its 10-year median of 154.22. Over the past 10 years, this metric has ranged from a low of 123.96 to a high of 243.22. The Drug Manufacturers industry median Days Payable is 90.69. Eris Lifesciences' value of 162.38 is 79% above this industry median. Based on the distribution chart, Eris Lifesciences ranks #198 out of 919 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Eris Lifesciences has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eris Lifesciences' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Eris Lifesciences ranks #198 out of 919 companies for Days Payable. This places Eris Lifesciences in the top 22% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.69. Eris Lifesciences' value of 162.38 is 79% above this benchmark. Historically, Eris Lifesciences' own Days Payable has ranged from 123.96 to 243.22 over the past decade. While the company's 10-year median is 154.22 vs. the industry median of 90.69, Eris Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.69, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eris Lifesciences's current Days Payable of 162.38 is 79% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Eris Lifesciences and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eris Lifesciences's current Days Payable is 162.38, which is near median its own 10-year median of 154.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eris Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Eris Lifesciences (BOM:540596) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,647.71, compared to a current price of ₹1,432.00 — trading 13.1% below its estimated fair value. The current Days Payable is 162.38, which is near median its 10-year median of 154.22 and 79% above the Drug Manufacturers industry median of 90.69. Eris Lifesciences' overall GF Score™ is 93/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Eris Lifesciences (BOM:540596), the current Days Payable is 162.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eris Lifesciences (BOM:540596) Overvalued in 2026?
Based on GuruFocus' analysis, Eris Lifesciences stock appears to be undervalued.
The current stock price of ₹1,432.00 is trading 13.1% below its estimated GF Value™ of ₹1,647.71.
GuruFocus considers Eris Lifesciences to be Modestly Undervalued.
Key valuation signals for BOM:540596:
Days Payable: 162.38 (near median its 10-year median of 154.22)
GF Value™: ₹1,647.71 vs. price of ₹1,432.00 (13.1% below fair value)
Industry Position: 79% above the Drug Manufacturers median (#198 of 919)
No single metric tells the full story. See the BOM:540596 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast. The company works basically within India and International with the majority of revenue from India.
93GF Score
Get the complete analysis for BOM:540596
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540596 has been successfully added to your 
